<DOC>
	<DOCNO>NCT01254994</DOCNO>
	<brief_summary>To evaluate therapeutic efficacy predict factor entecavir treat patient acute chronic hepatitis B liver failure ( ACHBLF ) . A total 108 patient ACHBLF allocate either treatment group ( ETV group , n=53 ) control group ( n=55 ) . The HBV DNA level , liver function survival condition patient observe 48 week enrollment . The factor possibly related entecavir treatment efficacy also identify .</brief_summary>
	<brief_title>The Efficacy Safety Entecavir Treatment Patients With Acute Chronic Hepatitis B Liver Failure</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>ACHBLF diagnose accord criterion APASL March 200815 program Prevention Cure Viral Hepatitis Liver Disease amend National Symposium Viral Hepatitis Liver Disease September 2000. age &gt; 18 year HBV DNA &gt; 3log10 copy/mL Pregnant lactate woman . Diagnosed suspected hepatic carcinoma patient . Cases serious disease besides CHB , include heart disease , immunologic disease , malignant tumor , etc . Patients hypersensitive nucleoside nucleoside ( acid ) analogues history nucleoside antiviral drug treatment . A history drug abuse alcohol abuse . Hepatic encephalopathy degree IV patient unable take orally administer drug . A history use immunomodulator include steroid Conclusive evidence co infection : antiHAVIgM positive , antiHCV positive , antiHEV positive , antiHIV positive , autoimmunity liver disease , Wilson disease , etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>acute chronic liver failure ( ACHBLF )</keyword>
	<keyword>entecavir</keyword>
	<keyword>treatment</keyword>
	<keyword>predict</keyword>
</DOC>